To examine whether downregulation of A9 would sensitize the RCC cells to SF treatment, we generated A9 shRNA transfectants of both 786-O and Caki-1 cells using two different shRNA constructs. This evidence concerns the gene IGKV1D-22 and renal cell carcinoma.